FULC Fulcrum Therapeutics Inc - Ordinary Shares

18.98
-0.91  -5%
Previous Close 19.89
Open 20
Price To Book 4.33
Market Cap 443,003,525
Shares 23,340,544
Volume 60,474
Short Ratio
Av. Daily Volume 65,318
Stock charts supplied by TradingView

NewsSee all news

  1. Fulcrum Therapeutics Appoints Katina Dorton to its Board of Directors

    CAMBRIDGE, Mass., Jan. 06, 2020 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (NASDAQ:FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare

  2. Acceleron and Fulcrum Therapeutics Announce Pulmonary Research and Discovery Collaboration Agreement

    Fulcrum to receive $10 million upfront payment and be eligible for future milestone payments Acceleron Pharma Inc. (NASDAQ:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta

  3. Fulcrum Therapeutics to Present at the 31st Annual Piper Jaffray Healthcare Conference

    CAMBRIDGE, Mass., Dec. 02, 2019 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (NASDAQ:FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare

  4. Fulcrum Therapeutics Reports Third Quarter 2019 Financial Results and Recent Business Highlights

    – Announced preliminary results of a Phase 1 clinical trial of losmapimod in FSHD patients – – Initiated IND-enabling studies for FTX-6058 for the potential treatment of sickle cell disease and beta-thalassemia and

  5. Fulcrum Therapeutics to Present at the Stifel 2019 Healthcare Conference

    CAMBRIDGE, Mass., Nov. 13, 2019 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (NASDAQ:FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2b trial initiation announced August 19, 2019. Data due 3Q 2020.
Losmapimod
Facioscapulohumeral muscular dystrophy (FSHD)
Phase 2 open-label initiation announced August 19, 2019.
Losmapimod
Facioscapulohumeral muscular dystrophy (FSHD)

Latest News

  1. Fulcrum Therapeutics Appoints Katina Dorton to its Board of Directors

    CAMBRIDGE, Mass., Jan. 06, 2020 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (NASDAQ:FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare

  2. Acceleron and Fulcrum Therapeutics Announce Pulmonary Research and Discovery Collaboration Agreement

    Fulcrum to receive $10 million upfront payment and be eligible for future milestone payments Acceleron Pharma Inc. (NASDAQ:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta

  3. Fulcrum Therapeutics to Present at the 31st Annual Piper Jaffray Healthcare Conference

    CAMBRIDGE, Mass., Dec. 02, 2019 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (NASDAQ:FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare

  4. Fulcrum Therapeutics Reports Third Quarter 2019 Financial Results and Recent Business Highlights

    – Announced preliminary results of a Phase 1 clinical trial of losmapimod in FSHD patients – – Initiated IND-enabling studies for FTX-6058 for the potential treatment of sickle cell disease and beta-thalassemia and

  5. Fulcrum Therapeutics to Present at the Stifel 2019 Healthcare Conference

    CAMBRIDGE, Mass., Nov. 13, 2019 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (NASDAQ:FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare

  6. Fulcrum Therapeutics to Report Third Quarter 2019 Financial Results on Thursday, November 14, 2019

    CAMBRIDGE, Mass., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (NASDAQ:FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare

  7. Fulcrum Therapeutics to Host Key Opinion Leader Breakfast Symposium on Facioscapulohumeral Dystrophy (FSHD), on November 7, 2019

    CAMBRIDGE, Mass., Oct. 31, 2019 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (NASDAQ:FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare

  8. Fulcrum Therapeutics Announced Results of Phase 1 Clinical Trial of Losmapimod in FSHD

    CAMBRIDGE, Mass., Oct. 04, 2019 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (NASDAQ:FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare

  9. Fulcrum Therapeutics Announces Multiple Presentations of Losmapimod Data at World Muscle Society Meeting

    Oral presentation to highlight Phase 1 data on safety, tolerability and target engagement of losmapimod in treatment of FSHDCompany also announces updated preclinical data on FTX-6058 for potential treatment of sickle